NSCLC个体化治疗的昨天和今天-1-update.pptVIP

EGFR突变状态是EGFR-TKI药物 疗效预测因子得到进一步验证 作者 Mok Lee Mitsudomi Maemondo Zhou Rosell 研究 IPASS First-SIGNAL WJTOG 3405 NEJGSG002 OPTIMAL EURTAC N ( EGFR 突变+ ) 261 42 174 230 154 175 RR 71.2% vs 47.3 84.6% vs 37.5% 62.1% vs 32.2% 73.7% vs 30.7% 83% vs 36% 83% vs 36% 中位 PFS (月) 9.8 vs 6.4 8.4 vs 6.7 9.2 vs 6.3 10.8 vs 5.4 13.1 vs 4.6 9.7 vs 5.2 OS (月) 18.8 vs. 17.4 21.3 vs. 23.3 35.5 vs. 38.8 27.7 vs. 26.6 22.69 vs. 28.85 19.3 vs. 19.6 Mitsudomi T, et al. 201